BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

In a global online forum Tuesday night, scientific leaders from companies developing vaccines, therapies and diagnostics to address the COVID-19 outbreak discussed opportunities for collaboration, highlighted challenges, and called for sustained global initiatives to create...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Extra | Oct 8, 2019
Tools & Techniques

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

Cellular responses to oxygen levels, the focus of this year's Nobel Prize in Physiology or Medicine, are the targets of both inhibiting and activating therapies in clinical development for multiple diseases. William Kaelin, Peter Ratcliffe...
BC Extra | Aug 19, 2019
Company News

Roche taps Lilly exec Garraway for CMO, product development post

Roche (SIX:ROG; OTCQX:RHHBY) has tapped Levi Garraway, formerly SVP of oncology R&D and and Lilly Research Laboratories Novel Target Research at Eli Lilly and Co. (NYSE:LLY), as CMO and head of global product development. Garraway,...
BioCentury | Aug 16, 2019
Emerging Company Profile

A-Alpha Bio retools yeast mating for high throughput drug discovery

A-Alpha Bio is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles,...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
Items per page:
1 - 10 of 232
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

In a global online forum Tuesday night, scientific leaders from companies developing vaccines, therapies and diagnostics to address the COVID-19 outbreak discussed opportunities for collaboration, highlighted challenges, and called for sustained global initiatives to create...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Extra | Oct 8, 2019
Tools & Techniques

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

Cellular responses to oxygen levels, the focus of this year's Nobel Prize in Physiology or Medicine, are the targets of both inhibiting and activating therapies in clinical development for multiple diseases. William Kaelin, Peter Ratcliffe...
BC Extra | Aug 19, 2019
Company News

Roche taps Lilly exec Garraway for CMO, product development post

Roche (SIX:ROG; OTCQX:RHHBY) has tapped Levi Garraway, formerly SVP of oncology R&D and and Lilly Research Laboratories Novel Target Research at Eli Lilly and Co. (NYSE:LLY), as CMO and head of global product development. Garraway,...
BioCentury | Aug 16, 2019
Emerging Company Profile

A-Alpha Bio retools yeast mating for high throughput drug discovery

A-Alpha Bio is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles,...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
Items per page:
1 - 10 of 232